• ICH GCP
    • Dansk
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Magyar
    • Nederlands
    • Norsk
    • Polski
    • Português
    • Suomi
    • Svenska
    • Čeština
    • Русский
    • 日本語
    • 简体中文
    • 한국어
  • Regulations
    • USA (FDA)
    • UK (MHRA)
    • AUSTRALIA (NHMRC)
    • JAPAN (PMDA)
  • CRO List
  • Clinical Trials
    • US Clinical Trials Registry
    • EU Clinical Trials Registry
    • Pharmaceutical Companies
    • Clinical Research Labs
    • Clinical Research Events
    • Publications
    • Researchers
  • Jobs
  • Publications
  • News
  • Regulations
    • GLOBAL (ICH GCP)
    • USA (FDA)
    • UK (MHRA)
    • AUSTRALIA (NHMRC)
    • JAPAN (PMDA)
    • EU (EMA)
  • CRO List
  • Clinical Trials
    • US Clinical Trials Registry
    • EU Clinical Trials Registry
    • Pharmaceutical Companies
    • Clinical Research Labs
    • Service Companies
    • Clinical Research Events
    • Publications
    • Researchers
  • Jobs
  • Publications
  • News
Example: Heart Attack
  • Glossary
  • Understanding Clinical Trials

Search clinical trials for: First progression

Total 10000 results


  • NCT07594015
    Recruiting
    Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
    Recurrent Endometrial Cancer
  • NCT07431216
    Not yet recruiting
    A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
    Glioblastoma (GBM)
  • NCT07389265
    Recruiting
    Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer (CAPRI-3 GOIM)
    Metastatic Colorectal Cancer (mCRC)
  • NCT07324876
    Not yet recruiting
    A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
    RCC
  • NCT06856213
    Recruiting
    Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX)
    Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

This is a preview
Log in or create a free account to see all matching trials and use the full search.
Log in | Register

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.

«Manage Settings
Regulations
  • GLOBAL (ICH GCP)
  • USA (FDA)
  • UK (MHRA)
  • AUSTRALIA (NHMRC)
  • JAPAN (PMDA)
  • EU (EMA)
Resources
  • CRO List
  • Pharmaceutical Companies
  • Clinical Research Labs
  • Service Companies
  • Jobs
  • US Clinical Trials Registry
  • EU Clinical Trials Registry
Articles
  • Publications
  • News
  • About us / Our mission
Language
Dansk Deutsch English Español Français Italiano Magyar Nederlands Norsk Polski Português Suomi Svenska Čeština Русский 日本語 简体中文 한국어
  • Sitemap
  • Contact us
  • RSS feed
  • Privacy Policy
  • Disclaimer
© ICH GCP. All Rights Reserved.